Huarong Holdings: terminate the purchase of 100% equity of Xinchao biology and resume trading tomorrow
Financial Associated Press, Dec. 28 - Huarong holdings announced that the counterparty reached an agreement on non employment performance commitment and compensation, terminated the purchase of 100% equity of Shanghai Xinchao Biotechnology Co., Ltd., and the trading of the shares has resumed since the opening of the market on December 29, 2021.
This text is a result of machine translation.
Related companies：
In-depth
Technology
DeepSeek | China's AI Global Breakthrough and Ecosystem Restructuring
Mar 19, 2025 01:18 PM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Watson biology: 13 valent pneumococcal polysaccharide conjugate vaccine has been licensed in Morocco
Briefing Dec 12, 2021 05:48 PM
· Healthcare
Watson biology: Yuxi Watson plans to invest in the production and capacity expansion project of polysaccharide conjugate vaccine, with a total investment of 695 million yuan
Briefing Sep 02, 2021 02:06 PM
· Healthcare
Medical stocks continued to decline in the afternoon, with dongfulong falling more than 15%
Briefing Jul 29, 2021 10:01 AM
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%
See more
Read next
Insight
In-depth
Technology
DeepSeek | China's AI Global Breakthrough and Ecosystem Restructuring
Mar 19, 2025 01:18 PM
Insight
In-depth
Insight
In-depth
Automotive · Analysis
China's New Energy Intelligent Vehicle Industry Chain Enterprises Have Opened a New Era
Feb 27, 2025 03:42 PM
Insight
In-depth
Automotive · Analysis
AIEV Leads the Way into a New Era of Automotive Intelligence
Feb 27, 2025 03:27 PM